Treace to Present at Truist Securities MedTech Conference
May 28 2024 - 7:00AM
Treace Medical Concepts, Inc. (“Treace” or the “Company”)
(NasdaqGS: TMCI), a medical technology company driving a
fundamental shift in the surgical treatment of bunions and related
midfoot deformities through its flagship Lapiplasty® and
Adductoplasty® Procedures, today announced that John T. Treace,
Chief Executive Officer, and Mark L. Hair, Chief Financial Officer,
will participate in a fireside chat at the Truist Securities
MedTech Conference on Tuesday, June 18, 2024, beginning at
approximately 8:00 am Eastern Time.
A live webcast and replay of the fireside chat
will be available on the Company’s investor relations website at
https://investors.treace.com/.
Internet Posting of Information
Treace routinely posts information that may be
important to investors in the “Investor Relations” section of its
website at www.treace.com. The Company encourages investors and
potential investors to consult the Treace website regularly for
important information about Treace.
About Treace Medical Concepts
Treace Medical Concepts, Inc. is a medical
technology company with the goal of advancing the standard of care
for the surgical management of bunion and related midfoot
deformities. Bunions are complex 3-dimensional deformities that
originate from an unstable joint in the middle of the foot and
affect approximately 67 million Americans, of which Treace
estimates 1.1 million are annual surgical candidates. Treace has
pioneered and patented the Lapiplasty® 3D Bunion
Correction® System – a combination of instruments, implants,
and surgical methods designed to surgically correct all three
planes of the bunion deformity and secure the unstable joint,
addressing the root cause of the bunion and helping patients get
back to their active lifestyles. To further support the needs of
bunion patients, Treace has introduced its
Adductoplasty® Midfoot Correction System, designed for
reproducible surgical correction of the midfoot as well as its
Hammertoe PEEK Fixation System designed to address hammertoe, claw
toe and mallet toe deformities. The Company continues to expand its
footprint in the foot and ankle market with the introduction of its
SpeedPlate™ Rapid Compression Implants, an innovative fixation
platform with broad versatility across Lapiplasty® and
Adductoplasty® procedures, as well as other common bone fusion
procedures of the foot. For more information, please visit
www.treace.com.
To learn more about Treace, connect with us on
LinkedIn, Twitter, Facebook and Instagram.
Contacts:
Treace Medical ConceptsJulie Dewey, IRCChief
Communications & Investor Relations Officerjddewey@treace.com |
209-613-6945
Treace Medical Concepts (NASDAQ:TMCI)
Historical Stock Chart
From Jun 2024 to Jul 2024
Treace Medical Concepts (NASDAQ:TMCI)
Historical Stock Chart
From Jul 2023 to Jul 2024